Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
نویسندگان
چکیده
منابع مشابه
Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.
BACKGROUND AND OBJECTIVES Ongoing randomized trials seek to validate the efficacy of rituximab as an induction agent for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, no studies directly address the role of rituximab as maintenance therapy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS This retrospective study reports the authors' experience with continuous...
متن کاملImmunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
BACKGROUND Rituximab (RTX), a B cell-depleting anti-CD20 monoclonal antibody, is approved for treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Low immunoglobulin (Ig) levels have been observed surrounding RTX treatment. The association between the degree of Ig deficiency and infection risk is unclear in AAV patients. METHODS AAV patients treated with RTX f...
متن کاملRituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: single centre experience with 15 patients
Background. B-cell depletion with rituximab, a chimeric anti-CD20 antibody, is a novel treatment for refractory and relapsing ANCA-associated small-vessel vasculitis. Data are limited and most reports describe single patients or small numbers of patients followed prospectively. Methods. We report a single-centre experience with 15 patients who received rituximab for refractory or relapsing ANCA...
متن کاملRituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.
BACKGROUND B-cell depletion with rituximab, a chimeric anti-CD20 antibody, is a novel treatment for refractory and relapsing ANCA-associated small-vessel vasculitis. Data are limited and most reports describe single patients or small numbers of patients followed prospectively. METHODS We report a single-centre experience with 15 patients who received rituximab for refractory or relapsing ANCA...
متن کاملLong-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
OBJECTIVE Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be quite effective in the treatment of immune disorders resulting from autoantibodies. We prospectively studied the long-term effects of rituximab in 10 patients with anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis refractory to conventional therapy (n=3) or in second or subsequent relapse (n=7). ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Journal of the American Society of Nephrology
سال: 2010
ISSN: 1555-9041,1555-905X
DOI: 10.2215/cjn.08821209